557 related articles for article (PubMed ID: 33285283)
1. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study.
Alsharidah S; Ayed M; Ameen RM; Alhuraish F; Rouheldeen NA; Alshammari FR; Embaireeg A; Almelahi M; Adel M; Dawoud ME; Aljasmi MA; Alshammari N; Alsaeedi A; Al-Adsani W; Arian H; Awad H; Alenezi HA; Alzafiri A; Gouda EF; Almehanna M; Alqahtani S; Alshammari A; Askar MZ
Int J Infect Dis; 2021 Feb; 103():439-446. PubMed ID: 33285283
[TBL] [Abstract][Full Text] [Related]
2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
3. Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname.
Bihariesingh-Sanchit R; Bansie R; Ramdhani N; Mangroo R; Bustamente D; Diaz E; Fung A Foek C; Thakoer I; Vreden S; Choudhry Z; van 't Wout AB; Diavatopoulos DA; Nierich AP
mBio; 2023 Apr; 14(2):e0337922. PubMed ID: 36815780
[TBL] [Abstract][Full Text] [Related]
4. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19.
Briggs N; Gormally MV; Li F; Browning SL; Treggiari MM; Morrison A; Laurent-Rolle M; Deng Y; Hendrickson JE; Tormey CA; Desruisseaux MS
PLoS One; 2021; 16(7):e0254453. PubMed ID: 34320004
[TBL] [Abstract][Full Text] [Related]
5. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
Bar KJ; Shaw PA; Choi GH; Aqui N; Fesnak A; Yang JB; Soto-Calderon H; Grajales L; Starr J; Andronov M; Mastellone M; Amonu C; Feret G; DeMarshall M; Buchanan M; Caturla M; Gordon J; Wanicur A; Monroy MA; Mampe F; Lindemuth E; Gouma S; Mullin AM; Barilla H; Pronina A; Irwin L; Thomas R; Eichinger RA; Demuth F; Luning Prak ET; Pascual JL; Short WR; Elovitz MA; Baron J; Meyer NJ; Degnan KO; Frank I; Hensley SE; Siegel DL; Tebas P
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34788233
[TBL] [Abstract][Full Text] [Related]
7. Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19.
Fazeli A; Sharifi S; Behdad F; Okati S; Esmaielifar G; Jelveh N; Eshghi P; Mohammadi S
Transfus Apher Sci; 2022 Apr; 61(2):103321. PubMed ID: 34836825
[TBL] [Abstract][Full Text] [Related]
8. Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation.
Park H; Yu C; Pirofski LA; Yoon H; Wu D; Li Y; Tarpey T; Petkova E; Antman EM; Troxel AB;
BMC Infect Dis; 2024 Jun; 24(1):639. PubMed ID: 38926676
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
10. COVID 19 convalescent plasma: Is there still a place for CCP?
Moog R
Transfus Apher Sci; 2023 Apr; 62(2):103680. PubMed ID: 36870907
[TBL] [Abstract][Full Text] [Related]
11. Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (COVID-19) patients.
Ikeda S; Benzi E; Hensch LA; Devaraj S; Hui SR; Gandhi M; Fox KA; Teruya J; Munoz FM
Pediatr Int; 2022 Jan; 64(1):e15407. PubMed ID: 36326636
[TBL] [Abstract][Full Text] [Related]
12. Early mortality benefit with COVID-19 convalescent plasma: a matched control study.
Shenoy AG; Hettinger AZ; Fernandez SJ; Blumenthal J; Baez V
Br J Haematol; 2021 Feb; 192(4):706-713. PubMed ID: 33482025
[TBL] [Abstract][Full Text] [Related]
13. High-Dose Convalescent Plasma for Treatment of Severe COVID-19.
De Santis GC; Oliveira LC; Garibaldi PMM; Almado CEL; Croda J; Arcanjo GGA; Oliveira ÉAF; Tonacio AC; Langhi DM; Bordin JO; Gilio RN; Palma LC; Santos EV; Haddad SK; Prado BPA; Pontelli MC; Gomes R; Miranda CH; Auxiliadora Martins M; Covas DT; Arruda E; Fonseca BAL; Calado RT
Emerg Infect Dis; 2022 Mar; 28(3):548-555. PubMed ID: 35081022
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control study.
Klein MN; Wang EW; Zimand P; Beauchamp H; Donis C; Ward MD; Martinez-Hernandez A; Tabatabai A; Baddley JW; Bloch EM; Mullins KE; Fontaine MJ
J Clin Pathol; 2022 Aug; 75(8):564-571. PubMed ID: 33893156
[TBL] [Abstract][Full Text] [Related]
15. Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial.
Shoham S; Bloch EM; Casadevall A; Hanley D; Lau B; Gebo K; Cachay E; Kassaye SG; Paxton JH; Gerber J; Levine AC; Naeim A; Currier J; Patel B; Allen ES; Anjan S; Appel L; Baksh S; Blair PW; Bowen A; Broderick P; Caputo CA; Cluzet V; Cordisco ME; Cruser D; Ehrhardt S; Forthal D; Fukuta Y; Gawad AL; Gniadek T; Hammel J; Huaman MA; Jabs DA; Jedlicka A; Karlen N; Klein S; Laeyendecker O; Lane K; McBee N; Meisenberg B; Merlo C; Mosnaim G; Park HS; Pekosz A; Petrini J; Rausch W; Shade DM; Shapiro JR; Singleton JR; Sutcliffe C; Thomas DL; Yarava A; Zand M; Zenilman JM; Tobian AAR; Sullivan DJ
Clin Infect Dis; 2023 Feb; 76(3):e477-e486. PubMed ID: 35579509
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial.
Ortigoza MB; Yoon H; Goldfeld KS; Troxel AB; Daily JP; Wu Y; Li Y; Wu D; Cobb GF; Baptiste G; O'Keeffe M; Corpuz MO; Ostrosky-Zeichner L; Amin A; Zacharioudakis IM; Jayaweera DT; Wu Y; Philley JV; Devine MS; Desruisseaux MS; Santin AD; Anjan S; Mathew R; Patel B; Nigo M; Upadhyay R; Kupferman T; Dentino AN; Nanchal R; Merlo CA; Hager DN; Chandran K; Lai JR; Rivera J; Bikash CR; Lasso G; Hilbert TP; Paroder M; Asencio AA; Liu M; Petkova E; Bragat A; Shaker R; McPherson DD; Sacco RL; Keller MJ; Grudzen CR; Hochman JS; Pirofski LA; ; Parameswaran L; Corcoran AT; Rohatgi A; Wronska MW; Wu X; Srinivasan R; Deng FM; Filardo TD; Pendse J; Blaser SB; Whyte O; Gallagher JM; Thomas OE; Ramos D; Sturm-Reganato CL; Fong CC; Daus IM; Payoen AG; Chiofolo JT; Friedman MT; Wu DW; Jacobson JL; Schneider JG; Sarwar UN; Wang HE; Huebinger RM; Dronavalli G; Bai Y; Grimes CZ; Eldin KW; Umana VE; Martin JG; Heath TR; Bello FO; Ransford DL; Laurent-Rolle M; Shenoi SV; Akide-Ndunge OB; Thapa B; Peterson JL; Knauf K; Patel SU; Cheney LL; Tormey CA; Hendrickson JE
JAMA Intern Med; 2022 Feb; 182(2):115-126. PubMed ID: 34901997
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes.
Yokoyama APH; Wendel S; Bonet-Bub C; Fachini RM; Dametto APF; Blumm F; Dutra VF; Candelaria GTP; Sakashita AM; Machado RRG; Fontão-Wendel R; Hamerschlak N; Achkar R; Assunção MSC; Scuracchio P; Nudelman V; Pastore L; Pinho JRR; Ben MD; Filho RK; Marra AR; Amano MT; Kallás EG; Helito AS; de Carvalho CRR; Araujo DB; Durigon EL; Camargo AA; Rizzo LV; Reis LFL; Kutner JM
Transfusion; 2021 Aug; 61(8):2295-2306. PubMed ID: 34173248
[TBL] [Abstract][Full Text] [Related]
18. Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients.
Arrieta A; Galvis AE; Morphew T; Ehwerhemuepha L; Osborne S; Enriquez C; Imfeld K; Hoang J; Nieves D; Ashouri N; Singh J; Nugent D
Pediatr Infect Dis J; 2021 Jul; 40(7):606-611. PubMed ID: 33967228
[TBL] [Abstract][Full Text] [Related]
19. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.
Körper S; Weiss M; Zickler D; Wiesmann T; Zacharowski K; Corman VM; Grüner B; Ernst L; Spieth P; Lepper PM; Bentz M; Zinn S; Paul G; Kalbhenn J; Dollinger MM; Rosenberger P; Kirschning T; Thiele T; Appl T; Mayer B; Schmidt M; Drosten C; Wulf H; Kruse JM; Jungwirth B; Seifried E; Schrezenmeier H;
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34464358
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19.
Sanz C; Nomdedeu M; Pereira A; Sauleda S; Alonso R; Bes M; Brillembourg H; García-Vidal C; Millan A; Martínez-Llonch N; Pirón M; Puerta-Alcalde P; Puig L; Rico V; Soriano A
Transfusion; 2022 May; 62(5):974-981. PubMed ID: 35338710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
